Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives

Bladder cancer (BC) is the most common malignancy of the genitourinary tract, with high morbidity and mortality rates. Until recently, the treatment of locally advanced or metastatic urothelial BC was based on the use of chemotherapy alone. Since 2016, five immune checkpoint inhibitors (ICIs) have b...

Full description

Bibliographic Details
Main Authors: Giandomenico Roviello, Martina Catalano, Raffaella Santi, Valeria Emma Palmieri, Gianmarco Vannini, Ilaria Camilla Galli, Eleonora Buttitta, Donata Villari, Virginia Rossi, Gabriella Nesi
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
urothelial carcinoma
bladder cancer
PD-1
PD-L1
immune checkpoint blockade
biomarkers
Online Access:https://www.mdpi.com/2072-6694/13/17/4411

Internet

https://www.mdpi.com/2072-6694/13/17/4411

Similar Items